BIOGEN INC.
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Why Biogen Stock Topped the Market Today
The company published its second-quarter results on Wednesday morning.
Biogen Inc. Q2 2026 Earnings Call Summary
Moby summary of Biogen Inc.'s Q2 2026 earnings call
Biogen: The Turnaround Is Real Enough To Buy (Rating Upgrade)
Biogen Inc. upgraded to Buy: Q2 revenue +3%, LEQEMBI traction, and felzartamab catalysts drive upside. Click for this BIIB earnings update.
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?
Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals
HRMY, ACAD, BIIB, INSM and AGIO are set to report Q2 results, with positive Earnings ESPs suggesting potential earnings surprises.
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.
Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?
BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors watch Leqembi trends and the Apellis deal impact.
Biogen And The Limitation Of The Tau Approach To Alzheimer's Disease
Biogenâs (BIIB) FDA-approved injectable Leqembi cuts infusion costs but risks brain bleeds; see how diranersen compares and why neither may boost valuation.
Guggenheim Maintains Buy on Biogen, Raises Price Target to $280
Guggenheim analyst Brad Canino maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $260 to $280.
B of A Securities Maintains Neutral on Biogen, Lowers Price Target to $215
B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $217 to $215.
Congressional Trades in $BIIB
Insider Trades (Form 4)
HAWKINS WILLIAM A
SHERWIN STEPHEN A
Rowinsky Eric K
Mantas Jesus B
LANGER SUSAN
Patolawala Monish D
Key People
LANGER SUSAN
Director
HAWKINS WILLIAM A
Director
Patolawala Monish D
Director
Mantas Jesus B
Director
SHERWIN STEPHEN A
Director
Rowinsky Eric K
Director
Political Giving
$30,500 given to 15 candidates across 20 disclosed contributions (FEC Schedule A).
Lori Trahan
Gus M. Bilirakis
Katherine M. Clark
Kevin Hern
Ashley Moody
Jake Auchincloss
Markwayne Mullin
Bill Cassidy
Susan M. Collins
Nanette Barragan
Terri A. Sewell
Blake Moore
Suzan K. DelBene
Brad Knott
Deborah Ross
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro